Market Outlook on 2022 Ranirestat Market Healthcare Report

1
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to
2022byGlobalData

• Explore all reports for Life Sciences market
• _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces .

2
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• The entire market for micro vascular
  complications of diabetes (MCD) diabetic
  nephropathy, retinopathy, and neuropathy is
  facing an extremely high level of unmet need
  across the 7MM (US, 5EU and Japan). Despite its
  enormous potential, the MCD market is facing the
  major global barrier in the sparsely populated
  pipeline. The diabetic retinopathy segment of the
  market has recently seen rapid uptake of novel
  anti-VEGF therapies and is experiencing a strong
  growth. On the other hand, the diabetic
  neuropathy and nephropathy segments face the
  barrier in and increasing number of generic
  competitors.
• Ranirestat is being developed jointly by
  Dainippon Sumitomo Pharma and Eisai for the
  treatment of diabetic neuropathy. The drug is
  currently in Phase III trials in Japan and
  recently completed Phase II/III trials in the US
  and Europe. Ranirestat is a selective inhibitor
  of AR, a key enzyme in the polyol pathway
  associated with the conversion of glucose to
  sorbitol.
• Request a sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147164 .

3
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• Scope
• Overview of MCD, including epidemiology,
  etiology, symptoms, diagnosis, pathology and
  treatment guidelines as well as an overview on
  the competitive landscape.
• Detailed information on Ranirestat including
  product description, safety and efficacy profiles
  as well as a SWOT analysis.
• Sales forecast for Ranirestat from 2012 to 2022.
• Sales information covered for Japan.
• Complete report available _at_ http//www.rnrmarketre
  search.com/ranirestat-microvascular-complications-
  of-diabetes-forecast-and-market-analysis-to-2022-m
  arket-report.html .

4
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• Reasons to buy
• Understand and capitalize by identifying products
  that are most likely to ensure a robust return
• Stay ahead of the competition by understanding
  the changing competitive landscape for MCD
• Effectively plan your MA and partnership
  strategies by identifying drugs with the most
  promising sales potential
• Make more informed business decisions from
  insightful and in-depth analysis of Ranirestat
  performance
• Obtain sales forecast for Ranirestat from
  2012-2022 in Japan.
• Inquire for discount on this report _at_
  http//www.rnrmarketresearch.com/contacts/discount
  ?rname147164 .

5
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• Table Of Contents
• 1 Table of Contents1 Table of Contents 61.1
  List of Tables 91.2 List of Figures 9
• 2 Introduction 102.1 Catalyst 102.2 Related
  Reports 11
• 3 Disease Overview 133.1 Etiology and
  Pathophysiology 153.1.1 Diabetic Nephropathy
  153.1.2 Diabetic Retinopathy 173.1.3 Diabetic
  Neuropathy 183.2 Prognosis 193.3 Quality of
  Life 203.4 Symptoms 21

6
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• 4 Disease Management 224.1 Treatment Overview
  224.1.1 Diagnosis and Referrals 224.1.2
  Screening 244.1.3 Treatment Guidelines 25
• 5 Competitive Assessment 335.1 Overview 335.2
  Strategic Competitor Assessment 34
• 6 Opportunity and Unmet Need 386.1 Overview
  386.2 Unmet Needs 396.2.1 Unified Treatment for
  the Microvascular Complications of Diabetes
  396.2.2 Optimization of Personalized Therapy in
  the Microvascular Complications of Diabetes
  396.2.3 Treatment for Diabetic Nephropathy that
  Would Prevent ESRD 416.2.4 Cardio- and
  Renoprotective Therapy for Diabetic Nephropathy
  42

7
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• 6.2.5 Efficient Therapy for Retinopathy 436.2.6
  Convenient Administration in Diabetic Retinopathy
  Treatment 436.2.7 Treatment for Diabetic
  Neuropathy 446.3 Unmet Needs Gap Analysis 456.4
  Opportunity Therapy for the Underlying Cause of
  the Microvascular Complications of Diabetes
  476.5 Opportunity Patient-Tailored Therapy for
  the Microvascular Complications of Diabetes
  476.6 Opportunity Efficacious Therapy for
  Diabetic Nephropathy 486.7 Opportunity Topical
  Treatment for Diabetic Retinopathy 486.8
  Opportunity Treatment for Diabetic Neuropathy 49
• 7 Pipeline Assessment 507.1 Overview 507.2
  Promising Drugs in Clinical Development 52
• Request a sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147164 .

8
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• 8 Ranirestat 548.1 Overview 548.2 Efficacy
  558.3 Safety 568.4 Dosing and Formulation
  568.5 Potential Clinical Positioning 568.6
  Potential Commercial Positioning 578.7 Pricing
  and Reimbursement 578.8 SWOT Analysis 578.9
  Forecast 58
• 9 Appendix 599.1 Bibliography 599.2
  Abbreviations 639.3 Methodology 659.4
  Forecasting Methodology 659.4.1 Diagnosed
  Patients 659.4.2 Percent Drug-Treated Patients
  66

9
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• 9.4.3 General Pricing Assumptions 669.4.4
  Generic Erosion 679.4.5 Pricing of Pipeline
  Agents 679.5 Physicians and Specialists Included
  in this Study 689.6 About the Authors 709.6.1
  Analyst II - CVMD 709.6.2 Therapy Director -
  CVMD and Infectious Disease 709.6.3 Global Head
  of Healthcare 719.7 About GlobalData 729.8
  Disclaimer 72
• List of Tables
• Table 1 Risk Factors for MCD 15Table 2
  Symptoms of MCD 21Table 3 Diagnostic Tests and
  Typical Criteria for MCD 23Table 4 Treatment
  Guidelines for MCD 26
• Table 5 Most Prescribed Drugs for MCD by Class
  in the 7MM, 2012 29Table 6 Leading Drug
  Treatments for MCD, 2013 36

10
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• Table 7 Overall Unmet Needs - Current Level of
  Attainment 38Table 8 Clinical Unmet Needs in
  MCD - Gap Analysis, 2012 46Table 9 MCD - Phase
  Pipeline, 2013 52Table 10 Comparison of Drugs
  in Development for MCD, 2013 53Table 11 Product
  Profile - Ranirestat 55Table 12 Ranirestat SWOT
  Analysis, 2013 57Table 13 Global Sales
  Forecasts (m) for Ranirestat, 2012-2022 58Table
  14 Number of High-Prescribing Physicians
  Surveyed 69
• List of Figures
• Figure 1 Potential Mechanisms of
  Diabetes-Induced Microvascular Complications
  14Figure 2 General Treatment Algorithms for MCD
  27Figure 3 Competitive Assessment of Late-Stage
  Pipeline Agents in MCD, 2012-2022
• Inquire for discount on this report _at_
  http//www.rnrmarketresearch.com/contacts/discount
  ?rname147164 .

11
Ranirestat (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.